Duchenne UK launches data-sharing initiative
The non-profit patient group Duchenne UK is collaborating with seven biotech and pharma companies and two universities to generate and share disease-level data to improve submissions for new treatments for Duchenne muscular dystrophy to Health Technical Assessment (HTA) regulatory bodies.
The organization launched Project Hercules with support from Pfizer Inc. (NYSE:PFE), PTC Therapeutics Inc. (NASDAQ:PTCT), Roche (SIX:ROG; OTCQX:RHHBY), Sarepta Therapeutics Inc. (NASDAQ:SRPT), Solid Biosciences LLC (Cambridge, Mass.), Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) and Wave Life Sciences Ltd. (NASDAQ:WVE), which are all developing DMD therapies. Additionally, University of Leicester and University of Sheffield partnered with the organization to develop metrics and data analysis...